open access

Vol 88, No 3 (2017)
Research paper
Published online: 2017-03-31
Get Citation

The −2549 insertion/deletion polymorphism of VEGF gene associated with uterine leiomyoma susceptibility in women from Southeastern Iran

Farshid Keshavarzi, Saeedeh Salimi, Abbas Mohammadpour-gharehbagh, Batool Teimoori, Atefeh Yazdi, Farzaneh Farajian-Mashhadi, Minoo Yaghmaei, Mojgan Mokhtari
DOI: 10.5603/GP.a2017.0022
·
Pubmed: 28397198
·
Ginekol Pol 2017;88(3):115-119.

open access

Vol 88, No 3 (2017)
ORIGINAL PAPERS Gynecology
Published online: 2017-03-31

Abstract

Objectives: Vascular endothelial growth factor (VEGF) is an important angiogenic factor that regulates angiogenesis and mediates sex steroid-induced cell growth. The present study investigated the association of VEGF gene-2578C/A (rs699947) and −2549 insertion/deletion polymorphisms in the promoter region of VEGF-A gene and uterine leiomyoma susceptibility in Southeast of Iran.

Material and methods: One hundred and fifty five women with uterine leiomyoma and 157 age, BMI, and ethnicity matched healthy women were enrolled in this study. VEGF gene –2578C/A polymorphism genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and the –2549 insertion/dele­tion polymorphism was analyzed by PCR method.

Results: The frequency of alleles and genotypes of VEGF-2578C/A polymorphism was not different between women with uterine leiomyoma and the controls; however, a significant association was revealed between II genotype of –2549 insertion/deletion (I/D) polymorphism of VEGF gene and uterine leiomyoma.

Conclusions: The findings showed that VEGF gene –2549 insertion/deletion polymorphism was associated with uterine leiomyoma.

Abstract

Objectives: Vascular endothelial growth factor (VEGF) is an important angiogenic factor that regulates angiogenesis and mediates sex steroid-induced cell growth. The present study investigated the association of VEGF gene-2578C/A (rs699947) and −2549 insertion/deletion polymorphisms in the promoter region of VEGF-A gene and uterine leiomyoma susceptibility in Southeast of Iran.

Material and methods: One hundred and fifty five women with uterine leiomyoma and 157 age, BMI, and ethnicity matched healthy women were enrolled in this study. VEGF gene –2578C/A polymorphism genotyping was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, and the –2549 insertion/dele­tion polymorphism was analyzed by PCR method.

Results: The frequency of alleles and genotypes of VEGF-2578C/A polymorphism was not different between women with uterine leiomyoma and the controls; however, a significant association was revealed between II genotype of –2549 insertion/deletion (I/D) polymorphism of VEGF gene and uterine leiomyoma.

Conclusions: The findings showed that VEGF gene –2549 insertion/deletion polymorphism was associated with uterine leiomyoma.

Get Citation

Keywords

VEGF, uterine leiomyoma, polymorphism

About this article
Title

The −2549 insertion/deletion polymorphism of VEGF gene associated with uterine leiomyoma susceptibility in women from Southeastern Iran

Journal

Ginekologia Polska

Issue

Vol 88, No 3 (2017)

Article type

Research paper

Pages

115-119

Published online

2017-03-31

DOI

10.5603/GP.a2017.0022

Pubmed

28397198

Bibliographic record

Ginekol Pol 2017;88(3):115-119.

Keywords

VEGF
uterine leiomyoma
polymorphism

Authors

Farshid Keshavarzi
Saeedeh Salimi
Abbas Mohammadpour-gharehbagh
Batool Teimoori
Atefeh Yazdi
Farzaneh Farajian-Mashhadi
Minoo Yaghmaei
Mojgan Mokhtari

References (31)
  1. Flynn M, Jamison M, Datta S, et al. Health care resource use for uterine fibroid tumors in the United States. Am J Obstet Gynecol. 2006; 195(4): 955–964.
  2. Marino JL, Eskenazi B, Warner M, et al. Uterine leiomyoma and menstrual cycle characteristics in a population-based cohort study. Hum Reprod. 2004; 19(10): 2350–2355.
  3. Özcan A, Kopuz A, Turan V, et al. Cesarean myomectomy for solitary uterine fibroids: Is it a safe procedure? Ginekol Pol. 2016; 87(1): 54–58.
  4. Faerstein E, Szklo M, Rosenshein N. Risk factors for uterine leiomyoma: a practice-based case-control study. I. African-American heritage, reproductive history, body size, and smoking. Am J Epidemiol. 2001; 153(1): 1–10.
  5. Strawn EY, Novy MJ, Burry KA, et al. Insulin-like growth factor I promotes leiomyoma cell growth in vitro. Am J Obstet Gynecol. 1995; 172(6): 1837–43; discussion 1843.
  6. Wang Y, Matsuo H, Kurachi O, et al. Down-regulation of proliferation and up-regulation of apoptosis by gonadotropin-releasing hormone agonist in cultured uterine leiomyoma cells. Eur J Endocrinol. 2002; 146(3): 447–456.
  7. Lethaby A, Vollenhoven B, Sowter M. Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids undergoing hysterectomy or myomectomy: a systematic review. BJOG. 2002; 109(10): 1097–1108.
  8. Parker WH. Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril. 2007; 87(4): 725–736.
  9. Flake GP, Andersen J, Dixon D. Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect. 2003; 111(8): 1037–1054.
  10. Gaitskell K, Martinek I, Bryant A, et al. Angiogenesis inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2011(9): CD007930.
  11. Kroep JR, Nortier JWR. The role of bevacizumab in advanced epithelial ovarian cancer. Curr Pharm Des. 2012; 18(25): 3775–3783.
  12. Yamazaki Y, Morita T. Molecular and functional diversity of vascular endothelial growth factors. Mol Divers. 2006; 10(4): 515–527.
  13. Roy H, Bhardwaj S, Ylä-Herttuala S. Biology of vascular endothelial growth factors. FEBS Lett. 2006; 580(12): 2879–2887.
  14. Jackson MR, Carney EW, Lye SJ, et al. Localization of two angiogenic growth factors (PDECGF and VEGF) in human placentae throughout gestation. Placenta. 1994; 15(4): 341–353.
  15. Wei MH, Popescu NC, Lerman MI, et al. Localization of the human vascular endothelial growth factor gene, VEGF, at chromosome 6p12. Hum Genet. 1996; 97(6): 794–797.
  16. Vincenti V, Cassano C, Rocchi M, et al. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996; 93(8): 1493–1495.
  17. Hsieh YY, Chang CC, Tsai FJ, et al. T allele for VEGF-460 gene polymorphism at 5'-untranslated region is associated with higher susceptibility of leiomyoma. Biochem Genet. 2008; 46(5-6): 356–361.
  18. Feng Yi, Lin X, Zhou S, et al. The associations between the polymorphisms of the ER-α gene and the risk of uterine leiomyoma (ULM). Tumour Biol. 2013; 34(5): 3077–3082.
  19. Hsieh YY, Chang CC, Tsai FJ, et al. Estrogen receptor thymine-adenine dinucleotide repeat polymorphism is associated with susceptibility to leiomyoma. Fertil Steril. 2003; 79(1): 96–99.
  20. Yaghmaei M, Salimi S, Namazi L, et al. Association of XRCC1 Arg399GIn and Tp53 Arg72Pro polymorphisms and increased risk of uterine leiomyoma - A case-control study. Genet Mol Biol. 2015; 38(4): 444–449.
  21. Wang F, Chen J, Wang L, et al. CYP1A1 genetic polymorphisms and uterine leiomyoma risk: a meta-analysis. Int J Clin Exp Med. 2015; 8(3): 3590–3594.
  22. Feng Yi, Zhao X, Zhou C, et al. The associations between the Val158Met in the catechol-O-methyltransferase (COMT) gene and the risk of uterine leiomyoma (ULM). Gene. 2013; 529(2): 296–299.
  23. Salimi S, Hajizadeh A, Khodamian M, et al. Age-dependent association of MDM2 promoter polymorphisms and uterine leiomyoma in South-East Iran: A preliminary report. J Obstet Gynaecol Res. 2015; 41(5): 729–734.
  24. Stoner M, Wang F, Wormke M, et al. Inhibition of vascular endothelial growth factor expression in HEC1A endometrial cancer cells through interactions of estrogen receptor alpha and Sp3 proteins. J Biol Chem. 2000; 275(30): 22769–22779.
  25. Adams J, Carder PJ, Downey S, et al. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res. 2000; 60(11): 2898–2905.
  26. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol. 2003; 10(4): 355–362.
  27. Henidi B, Kaabachi W, Naouali A, et al. Vascular endothelial growth factor (-460 C/T, +405 G/C, and +936 C/T) polymorphisms and endometriosis risk in Tunisian population. Syst Biol Reprod Med. 2015; 61(4): 238–244.
  28. Perini J, Cardoso J, Berardo P, et al. Role of vascular endothelial growth factor polymorphisms (-2578C > A, -460 T > C, -1154G > A, +405G > C and +936C > T) in endometriosis: a case–control study with Brazilians. BMC Women's Health. 2014; 14(1).
  29. Zhao J, Li Y, Liu Q, et al. Association of single nucleotide polymorphisms in VEGF gene with the risk of endometriosis and adenomyosis. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2009; 26(2): 165–169.
  30. Kang S, Zhao J, Liu Q, et al. Vascular endothelial growth factor gene polymorphisms are associated with the risk of developing adenomyosis. Environ Mol Mutagen. 2009; 50(5): 361–366.
  31. Li YZ, Wang LJ, Li X, et al. Vascular endothelial growth factor gene polymorphisms contribute to the risk of endometriosis: an updated systematic review and meta-analysis of 14 case-control studies. Genet Mol Res. 2013; 12(2): 1035–1044.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl